CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Cytek Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$5.25+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $679.67M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
51.8%−7231.3 pts over 5 years
Operating margin
-20.0%−1943.8 pts over 5 years
Net margin
-33.0%−2767.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.5% | +7.1% | +209.5% | – | |
| Gross profit | -6.0% | +1.1% | +15.1% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 151.2% | -18.0% | |
| Return on assets | – | – | -13.8% | |
| Current ratio | – | 7.86 | 5.04 | |
| Interest coverage | – | 41.0× | -85.2× | |
| Inventory turnover | – | – | 2.1× | |
| Capex to revenue | – | 217.9% | 2.0% | |
| Diluted shares | – | 33M | 128M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cytek Biosciences generated $52.21M from operations and spent $107.21M on capital expenditure, dividends and share buybacks. 25% of that went back into the business.
Generated
$52.21M
Used
$107.21M
Capital expenditure$26.37M25%Dividends$00%Share buybacks$80.84M75%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-33.0%
×Asset turnover0.42×
×Equity multiplier1.30×
=Return on equity, FY2025-18.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -33.0% | 0.42× | 1.30× | -18.0% |
| FY2024 | -3.0% | 0.40× | 1.26× | -1.5% |
| FY2023 | -6.3% | 0.38× | 1.24× | -3.0% |
| FY2022 | 1.5% | 0.33× | 1.18× | 0.6% |
| FY2021 | 138.8% | 0.01× | 1.75× | 1.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$66.54M
- Cash generatingOperating cash flow above zero-$4.69M
- Return on assets improvedROA up on the prior year-1.2% → -13.3%
- Earnings backed by cashOperating cash flow above net income-$4.69M vs -$66.54M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.86 → 5.04
- No dilutionShare count did not rise131M → 128M
- Gross margin improvedGross margin up on the prior year55.43% → 51.84%
- More efficientAsset turnover rose0.41 → 0.40